Cell Death Dis:冷等离子体诱导肿瘤细胞死亡的机制

2020-05-20 QQY MedSci原创

在癌症治疗研究中,电离辐射以外的能够有效杀死癌细胞的新物理技术一直是一个研究热点。冷等离子体(CAP)是一种接近室温的电离气体,由反应性物质、离子、电子、中性粒子、紫外线、可见光等组成。在过去的十年研

在癌症治疗研究中,电离辐射以外的能够有效杀死癌细胞的新物理技术一直是一个研究热点。冷等离子体(CAP)是一种接近室温的电离气体,由反应性物质、离子、电子、中性粒子、紫外线、可见光等组成。在过去的十年研究中,CAP治疗手段已被认为是抗癌治疗中的一项强大而实用的技术,其显著的优势在于CAP可以有效地、选择性地杀死各种类型的肿瘤细胞,且对于正常细胞的损害明显更少。

活性氧(ROS)被认为是CAP诱导杀死肿瘤细胞的主要效应因子。目前许多研究表明,CAP暴露会增加细胞内ROS的水平,并导致DNA损伤、细胞周期停滞、线粒体损伤等,最终诱导肿瘤细胞凋亡或坏死。然而,目前尚不清楚CAP治疗是否可以诱导细胞焦亡这一除凋亡和坏死外的程序性细胞死亡的发生。

在该研究中,研究人员首次发现在GSDME(Gasdermin E)高表达的肿瘤细胞中,CAP能够以剂量依赖性的方式有效地诱导细胞焦亡的发生。有趣的是,在三种挑选的癌细胞系中,GSDME蛋白的基础水平与细胞对CAP的敏感性呈正相关,这也意味着GSDME可能是CAP治疗策略中癌症预后的一个潜在的生物标志物。此外,研究人员发现CAP诱导的细胞焦亡依赖于线粒体途径的激活(JNK/细胞色素c/caspase-9/caspase-3)以及GSDME的剪切作用,而非GSDMD(Gasdermin D)。CAP诱导的ROS的产生也被证实能够启动细胞焦亡信号。

以上的研究结果丰富了我们对冷等离子体诱导的细胞死亡的认识,并为优化其在癌症治疗中的应用提供了参考。

原始出处:

评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
    2025-11-20 侠胆医心 来自加利福尼亚

    这篇基于Cell Death & Disease杂志发表的综述,聚焦于#冷等离子体#(CAP)诱导#肿瘤细胞#死亡的分子机制,尤其揭示CAP可通过增加#活性氧#(ROS)产物,触发#GSDME#依赖的#细胞焦亡#途径,为优化CAP抗#癌症#治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种#肿瘤#类型细胞死亡的特性,显示其在#实体瘤#治疗中的潜力。 指出#GSDME#蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的#生物标志物#,对于精准个体化治疗具有实际指导意义。 揭示了#线粒体信号通路#(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导#程序性细胞死亡#中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际#转化应用#进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对#安全性#、潜在副作用以及与现有#放化疗##免疫治疗#联合策略的系统性讨论,后续可拓展关于#联合治疗#模式探索及其对耐药肿瘤影响的研究。 #病例选择标准##剂量优化##CAP处理参数#等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对#肿瘤免疫微环境##肿瘤干细胞#的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进#冷等离子体#在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释#安全性##有效性#、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
    2020-09-30 zhaozhouchifen

    #Cell#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
    2020-09-08 weihongyv
  4. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
    2021-02-24 cmj8wellington

    #Dis#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
    2021-01-28 维他命

    #CEL#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
    2020-05-22 hmwwww
  8. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
    2020-05-22 cy0328

    #Death#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
    2020-05-21 thm112988

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2289698, encodeId=ba55228969849, content=这篇基于Cell Death & Disease杂志发表的综述,聚焦于<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>(CAP)诱导<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>死亡的分子机制,尤其揭示CAP可通过增加<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>(ROS)产物,触发<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>依赖的<a href='/topic/show?id=bd5be795632' target=_blank style='color:#2F92EE;'>#细胞焦亡#</a>途径,为优化CAP抗<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a>治疗应用提供了新思路。​ 临床实用性与价值评述: 该文阐释了冷等离子体在杀伤肿瘤细胞中的优势,特别是其对正常组织损伤较小、可有效诱导多种<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>类型细胞死亡的特性,显示其在<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>治疗中的潜力。 指出<a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4dff11e79463' target=_blank style='color:#2F92EE;'>#GSDME#</a></a>蛋白表达水平与CAP敏感性密切相关,提示GSDME有望成为判断肿瘤CAP治疗预后的<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>,对于精准个体化治疗具有实际指导意义。 揭示了<a href='/topic/show?id=b31013219eac' target=_blank style='color:#2F92EE;'>#线粒体信号通路#</a>(JNK/细胞色素c/caspase-9/caspase-3/GSDME剪切)在CAP诱导<a href='/topic/show?id=c79de52658f' target=_blank style='color:#2F92EE;'>#程序性细胞死亡#</a>中的关键作用,为开发联合靶向治疗方案提供了分子基础。 当前文章的不足与可补充内容: 文章目前以细胞及分子实验为主,缺乏动物模型及初步临床研究数据,对于CAP治疗的实际<a href='/topic/show?id=706593282bb' target=_blank style='color:#2F92EE;'>#转化应用#</a>进展描述较少,未来可补充更多体内验证及临床前/早期临床试验内容。 缺乏对<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、潜在副作用以及与现有<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>、<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>联合策略的系统性讨论,后续可拓展关于<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>模式探索及其对耐药肿瘤影响的研究。 <a href='/topic/show?id=e3f2132198d4' target=_blank style='color:#2F92EE;'>#病例选择标准#</a>、<a href='/topic/show?id=915d132199ce' target=_blank style='color:#2F92EE;'>#剂量优化#</a>、<a href='/topic/show?id=b2991322002b' target=_blank style='color:#2F92EE;'>#CAP处理参数#</a>等关键技术细节未详述,未来需系统总结标准化操作指导以促进多中心推广。 对免疫微环境、抗肿瘤免疫应答调控的影响未涉及,补充CAP对<a href='/topic/show?id=026382811f6' target=_blank style='color:#2F92EE;'>#肿瘤免疫微环境#</a>和<a href='/topic/show?id=76bf8290642' target=_blank style='color:#2F92EE;'>#肿瘤干细胞#</a>的影响,有助于全面评估其临床应用潜力。 总评: 这项综述对于推进<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a></a>在精准抗癌治疗领域的基础研究与早期临床转化具有重要学术价值,但仍需跨越基础与临床之间的“鸿沟”。建议未来从多维度进一步阐释<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a></a>、<a href='/topic/show?id=713560611e8' target=_blank style='color:#2F92EE;'>#有效性#</a>、#免疫调控#及#临床转化路径#等,为CAP抗癌技术临床应用提供坚实证据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29065, encryptionId=daf52906537, topicName=免疫治疗), TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性), TopicDto(id=46016, encryptionId=13db460162d, topicName=实体瘤), TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗), TopicDto(id=60611, encryptionId=713560611e8, topicName=有效性), TopicDto(id=65217, encryptionId=b79c6521eb7, topicName=活性氧), TopicDto(id=69366, encryptionId=5df56936690, topicName=生物标志物), TopicDto(id=71301, encryptionId=d8dbe130197, topicName=癌症), TopicDto(id=75265, encryptionId=c79de52658f, topicName=程序性细胞死亡), TopicDto(id=77956, encryptionId=bd5be795632, topicName=细胞焦亡), TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗), TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤), TopicDto(id=82811, encryptionId=026382811f6, topicName=肿瘤免疫微环境), TopicDto(id=82906, encryptionId=76bf8290642, topicName=肿瘤干细胞), TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞), TopicDto(id=93282, encryptionId=706593282bb, topicName=转化应用), TopicDto(id=117794, encryptionId=4dff11e79463, topicName=GSDME), TopicDto(id=132197, encryptionId=b31013219eac, topicName=线粒体信号通路), TopicDto(id=132198, encryptionId=e3f2132198d4, topicName=病例选择标准), TopicDto(id=132199, encryptionId=915d132199ce, topicName=剂量优化), TopicDto(id=132200, encryptionId=b2991322002b, topicName=CAP处理参数)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Nov 20 04:41:33 CST 2025, time=2025-11-20, status=1, ipAttribution=加利福尼亚), GetPortalCommentsPageByObjectIdResponse(id=1871760, encodeId=7cbd18e17600d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 30 03:05:27 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004310, encodeId=109620043108d, content=<a href='/topic/show?id=249de5899f6' target=_blank style='color:#2F92EE;'>#等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75899, encryptionId=249de5899f6, topicName=等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Tue Sep 08 17:05:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971110, encodeId=310f19e11109b, content=<a href='/topic/show?id=bbb53115823' target=_blank style='color:#2F92EE;'>#冷等离子体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31158, encryptionId=bbb53115823, topicName=冷等离子体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jun 16 17:05:27 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013365, encodeId=5265201336548, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Feb 24 06:05:27 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962056, encodeId=e13d19620565a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 28 05:05:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313061, encodeId=6eb813130614c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531633, encodeId=0606153163371, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri May 22 14:05:27 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383009, encodeId=5194383009ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Thu May 21 06:59:50 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039242, encodeId=1cb610392420c, content=机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 21 02:05:27 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
    2020-05-21 肿肿

    机制研究离临床仍然有距离,不过与临床结合思考,仍然有帮助的,不能仅仅是纯临床思维,转化思维同样重要

    0

相关资讯

Nature: 癌症治疗的概念性突破:三特异性抗体靶向治疗方法

疫治疗的核心是增强免疫系统对肿瘤细胞的响应。最新开发的抗体经过改造,能够同时识别三个靶点。动物实验表明,这种抗体有望增强T细胞的抗肿瘤能力。

Crit Care Med:脓毒症和感染性休克对癌症患者的影响

随着时间的推移,患脓毒症的危重肿瘤和血液系统肿瘤患者的生存率显著提高。随着结局的改善,临床医生应考虑更新此类人群的入院政策和治疗目标。

国家药监局优先审评审批,新一代国产肺癌创新药上市

新一代国产肺癌创新药“阿美替尼”正式上市。

感谢复工体检偶遇热心医生,一句“问医”助力患者躲过“癌劫”

“感谢市六医院多学科医护人员的搭救之恩,否则肠道肿瘤肆意侵润,自己还蒙在鼓里。”家住浠水返汉务工的53岁吴秀芳(化名)对记者说道,复工体检后,自己不经意间的一句腹部偶尔隐隐胀痛

Nature子刊:禁食+维生素C+化疗的三联疗法对难治疗的癌症有效

5月11日发表在《自然通讯》上的研究表明,禁食与维生素C的结合对难治疗的癌症有效果。

J INTERN MED:房颤伴有癌症患者缺血性卒中后口服抗凝药的使用情况

在过去十年中,口服抗凝剂(OAC)的房颤(AF)患者数量有所增加。近日,内科学领域权威杂志Journal of Internal Medicine上发表一篇研究文章,研究人员旨在描述AF和活动性癌症患